Precision Radiotheranostics — The Biology of "Treat What You See"
Theranostics is the integration of diagnostic imaging and targeted therapy into a single drug platform. In oncology, this primarily manifests as Radiotheranostics, where a specific molecular "vector" (like a peptide or antibody) is tagged with different isotopes for different purposes.
The Diagnostic Phase: Clinicians use a positron-emitting isotope (e.g., Gallium-68) attached to a targeting vector to perform a PET scan. This allows for the visualization of specific receptors, such as Prostate-Specific Membrane Antigen ($PSMA$) in prostate cancer or Somatostatin Receptors ($SSTR$) in neuroendocrine tumors.
The Therapeutic Phase: Once the targets are confirmed, the diagnostic isotope is swapped for a particle-emitting therapeutic isotope (e.g., Lutetium-177 or Actinium-225).
The primary clinical advantage in 2026 is the "Crossfire Effect." While $\alpha$-emitters like Actinium-225 provide high-energy, short-range destruction (perfect for micrometastases), $\beta$-emitters like Lutetium-177 travel further within a tumor mass, ensuring that adjacent cancer cells—even those lacking the specific target receptor—are neutralized by secondary radiation.